Skip to search formSkip to main contentSkip to account menu

NSC 320846

Known as: NSC-320846 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

batracylin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Comparative Metabolism of Batracylin (NSC 320846) and N-acetylbatracylin (NSC 611001) Using Human, Dog, and Rat Preparations In Vitro.
BACKGROUND Batracylin is a heterocyclic arylamine topoisomerase inhibitor with preclinical anticancer activity. Marked species… 
Highly Cited
2007
Highly Cited
2007
Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage.
Batracylin (8-aminoisoindolo [1,2-b]quinazolin-10(12H)-one; NSC320846) is an investigational clinical anticancer agent. Previous… 
2007
2007
Batracylin, 8-aminoisoindolo [1,2-b]quinazolin-10(12H)-one (NSC 320846), a dual inhibitor of DNA topoisomerases I and II: molecular mechanisms and γ-H2AX as a biomarker of DNA damage.
A172 Batracylin (8-aminoisoindolo [1,2-b]quinazolin-10(12H)-one; NSC320846) is an investigational clinical anticancer agent… 
1991
1991
Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat
SummaryBatracylin (NSC-320846) is a quinalzolineone recently evaluated as a potential antitumor agent by the National Cancer… 
1989
1989
Activity of batracylin (NSC-320846) against solid tumors of mice
SummaryBatracylin (NSC 320846) is a water insoluble, solid tumor active compound discovered by the Developmental Therapeutics… 
1988
1988
Preclinical antitumor activity of batracylin (NSC 320846)
SummaryBatracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose of 400 mg/kg, inhibited tumor growth completely in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)